Enzo Biochem Inc.
(NYSE: ENZ) today announced the launch of the ColonSentry™ test for assessing a patient’s risk of having colorectal cancer, the first in a pipeline of new molecular diagnostic products the Company plans for the medical community.
“As a pioneer in the use of genomic and genetic information as a catalyst for diagnostic products for delivering better healthcare, the availability of ColonSentry™, which only recently received New York State Department of Health approval, marks another important chapter in the transformation of our Company,” said Barry Weiner, Enzo President.
“We also have, pending for New York State approval, our first assay based test on our new proprietary low cost and highly sensitive AmpiProbe™ nucleic acid amplification and detection technology platform. Our AmpiProbe™ HCV RNA Quantification assay has been tested over hundreds of clinical samples and found to be reliable, accurate and precise. In addition, our assay was found, as compared to similar diagnostics products, to achieve enhanced sensitivity that can allow for a more convenient and efficient workflow which may utilize significantly less starting material and consumables. This product is the first of several assays now under development based on the AmpiProbe™ next generation molecular diagnostics platform that are expected to be marketed both nationally and internationally.
“These developments underscore the opportunities available to our Company through the combination of a world class clinical lab and ground breaking life science capability. Today’s announcement of the effective roll out of ColonSentry™ is a significant achievement pointing towards a highly promising era for Enzo.”
ColonSentry™ is a first of its kind blood-based risk stratification test for colorectal cancer. It utilizes RNA to measure the level of expression of seven specific genes. ColonSentry™ requires only a small sample of blood that can be easily collected during a routine physical exam. It is being made available as a tool to help assess a patients’ risk for colorectal cancer, and thus drive greater compliance for use of colonoscopies, which has been very low, and contribute to earlier detection of colorectal cancer.